GLP-1 RA use tied to lower rate of venous thromboembolism in diabetes

For sufferers with sort 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is related to a decrease threat for venous thromboembolism (VTE), based on a examine scheduled for presentation on the annual assembly of the American Society of Hematology, to be held from Dec. 7 to 10 in San Diego.

Cho Han Chiang, M.D., from Mount Auburn Hospital in Cambridge, Massachusetts, and colleagues examined whether or not GLP-1 RA use would scale back the chance for VTE amongst sufferers with T2DM in a retrospective, propensity score-matched multicenter database evaluation. Sufferers who obtained GLP-1 RAs have been in comparison with those that obtained dipeptidyl peptidase-4 (DPP-4) inhibitors; after propensity rating matching, the ultimate evaluation included two cohorts of 168,428 sufferers every.

The researchers discovered that the incidence of VTE was 11.0 versus 12.9 occasions per 1,000 patient-years within the GLP-1 RA and DPP-4 inhibitor cohorts, respectively, with an 18% decrease threat for VTE for these receiving GLP-1 RAs (hazard ratio [HR]0.82). In contrast with these on DPP-4 inhibitors, sufferers receiving GLP-1 RAs had a decrease threat for pulmonary embolism and deep venous thrombosis (HRs, 0.78 and 0.85, respectively). In a subgroup evaluation, the variations in VTE charges have been comparable for sufferers with and with out weight problems (HRs, 0.80 and 0.82, respectively).

“These outcomes help the speculation that use of GLP-1 RA can result in a discount in VTE threat,” the authors write. “Additional research are wanted to elucidate the mechanisms and causality underlying the affiliation between GLP-1 RA use and discount of VTE threat, and whether or not these findings prolong to sufferers utilizing GLP-1 RA for weight management with out T2DM.”

2024 HealthDay. All rights reserved.